Welcome to our dedicated page for Cosmos Health SEC filings (Ticker: COSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Cosmos Health Inc.’s multi-layered disclosures can feel like juggling a nutraceutical label, a pharma dossier, and a tele-health term sheet all at once. Each 10-K blends revenue from Sky Premium Life vitamins, Cana Laboratories contract manufacturing margins, and capital needs for AI-driven oncology research—details scattered over hundreds of pages.
Stock Titan’s AI steps in as your translator. Need the Cosmos Health quarterly earnings report 10-Q filing distilled to cash-flow trends? Our algorithms flag segment revenue shifts in seconds. Tracking Cosmos Health insider trading Form 4 transactions? Real-time alerts surface every executive stock move, while concise notes explain whether buys align with clinical milestones. Even the nuanced language in an 8-K about a new EU distribution pact is rendered into plain English, so you understand the impact without decoding legal jargon.
You’ll find every filing type the moment it hits EDGAR:
- 10-K and 10-Q reports with AI-generated key metrics and R&D spend charts
- Form 4 insider transactions—Cosmos Health Form 4 insider transactions real-time
- Proxy statements detailing Cosmos Health executive compensation structures
- 8-K material events explained, from tele-health acquisitions to new drug patents
Whether you’re comparing nutraceutical margins quarter over quarter, gauging pipeline progress, or watching for director share purchases, our platform converts complex documents into actionable context. Explore Cosmos Health SEC filings explained simply, save hours of manual review, and make confident decisions based on complete, current information.
COSMOS HEALTH INC. reported that Nasdaq notified the company on December 11, 2025 that it is not in compliance with the Nasdaq Listing Rule requiring a minimum bid price of $1.00 per share for 30 consecutive business days. The company now has 180 calendar days from December 11, 2025 to regain compliance by keeping its common stock closing bid price at or above $1.00 per share for at least 10 consecutive business days.
If the company does not otherwise regain compliance with this listing standard, it states that it intends to implement a reverse stock split to meet the rule. Nasdaq will also display an indicator with quotation information related to the company’s securities, signaling the current non-compliance status to the market.
Cosmos Health Inc. CEO Grigorios Siokas converted $70,000 of company debt into 168,472 shares of common stock on December 15, 2025. The shares, described as Exchange Shares under a Debt Exchange Agreement between Siokas and the company, were issued at $0.4155 per share, identified as the fair market value of the stock on that date.
After this transaction, Siokas directly beneficially owned 6,628,457 Cosmos Health common shares. He is listed as a director, chief executive officer, and a more than 10% owner of Cosmos Health Inc.
Cosmos Health Inc. (COSM) reported an insider transaction by Chief Executive Officer, director and 10% owner Grigorios Siokas. On 11/25/2025, Mr. Siokas acquired 55,732 shares of common stock at $0.628 per share through a debt-for-equity exchange.
Under a Debt Exchange Agreement between Mr. Siokas and the company, these Exchange Shares were issued in exchange for $35,000 of debt that Cosmos Health owed to him. Following this transaction, Mr. Siokas beneficially owns 6,383,625 shares of Cosmos Health common stock, held in direct ownership.
Cosmos Health Inc. (COSM) CEO, director and 10% owner Grigorios Siokas reported acquiring common stock through a debt-for-equity exchange. On 11/21/2025, he acquired 56,080 shares of common stock at $0.6776 per share, identified as Exchange Shares under a Debt Exchange Agreement between him and the company. The price reflects the fair market value of the stock on that date and was used to exchange $38,000 of debt the company owed to him. Following this transaction, he beneficially owned 6,327,893 shares of Cosmos Health common stock, held directly.
Cosmos Health Inc. (COSM) insider Grigorios Siokas increased his stake through a debt-for-equity exchange. On 11/20/2025, the CEO, director and 10% owner acquired 51,315 shares of common stock at $0.6236 per share. The shares were issued as "Exchange Shares" in satisfaction of $32,000 that the company owed to him under a debt exchange agreement, using the fair market value of the stock on that date.
After this transaction, Siokas beneficially owned 6,271,813 shares held directly. This was a non-cash transaction for the company, converting a payable to equity while increasing the CEO’s direct ownership.
Cosmos Health Inc. (COSM)Grigorios Siokas, acquired additional common shares through a debt-for-equity exchange. On November 19, 2025, he acquired 61,614 shares of common stock at $0.6492 per share, described as the fair market value of the stock on that date. The shares were issued in exchange for a total of
Cosmos Health Inc. (COSM) filed a Form 8-K stating that on November 17, 2025 it issued a press release announcing its financial results for the quarter and nine months ended September 30, 2025. The press release is included as Exhibit 99.1 and provides the detailed financial figures and commentary. The company notes that the information in Items 2.02 and 7.01 and in Exhibit 99.1 is being furnished, not filed, under securities law, which limits certain legal liabilities and how the information may be incorporated into other filings.
Cosmos Health Inc. filed a replacement Form S-3 shelf registering up to $200,000,000 of common stock, preferred stock, warrants, units and subscription rights to be offered from time to time after effectiveness. The filing also includes a prospectus supplement for an at-the-market offering of up to $100,000,000 of common stock through A.G.P., which will earn a 3% commission on gross proceeds.
The company notes that, as of November 6, 2025, 34,919,920 shares of common stock were outstanding, with 26,274,546 held by non‑affiliates. Our common stock last closed at $0.67 on November 6, 2025, and trades on Nasdaq as “COSM.”
Unless otherwise indicated in a supplement, net proceeds are intended for the acquisition of crypto assets as a treasury asset and for general corporate purposes and working capital. Sales under the ATM may occur at market prices “from time to time,” subject to Securities Act Rule 415 and public float constraints.
Cosmos Health Inc. (COSM) reported that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement. Nasdaq notified the company that the closing bid price of its common stock was at least $1.00 per share for 18 consecutive business days, from September 22, 2025 to October 15, 2025, and the matter is now closed.
The update follows a prior notice on November 6, 2024 that COSM was below the $1.00 threshold for 30 consecutive business days. The company furnished a press release about the compliance status under Regulation FD.
FAQ
What is the current stock price of Cosmos Health (COSM)?
What is the market cap of Cosmos Health (COSM)?
